Novo Holdings et al. in $20m round for Reapplix

Private life sciences investors Bo Jesper Hansen and Jan Struve also took part in the round alongside existing investors Novo Holdings and Vaekstfonden.

According to Crunchbase, the company has previously raised $5m over four funding rounds.

Reapplix will use the proceeds to commercialise its trademarked offering 3C Patch across the US.

The company has, at the same time, announced that it has received Medicare reimbursement coding instructions from the US Centers for Medicare and Medicaid Services (CMS) with a national average payment rate of $1,622.74. 

Company
Founded in 2008 and headquartered in Birkerød, Reapplix specialises in the biological treatment and management of diabetic foot ulcers. It has developed 3C Patch, a technique whereby a wound-healing patch is created from the patient's own blood. The company has sales and distribution teams in the US and Europe. According to its LinkedIn page, it employs fewer than 50 staff. 

People
Reapplix – James G Wetrich (president); Graeme Brookes (CEO).
Lauxera Capital – Samuel Levy (founding partner).

 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• Nordics
• Healthcare
• Nordic venture
• Denmark
• Nordic healthcare